AFP and hepatocellular carcinoma: In a prospective HBV+ cohort, this serum biomarker was proposed to be a novel HCC biomarker with a very good diagnostic performance for HCC, even in early stages and in patients with normal AFP values (<20 ng/mL) (AUROC of 0.87 ;CI 0.83–0.91) [75].